STOCK TITAN
  1. Home
  2. News
  3. PRPH

ProPhase Labs, Inc. - PRPH STOCK NEWS

Welcome to our dedicated page for ProPhase Labs news (Ticker: PRPH), a resource for investors and traders seeking the latest updates and insights on ProPhase Labs stock.

ProPhase Labs, Inc. (PRPH) is a diversified natural health medical science company that specializes in providing a wide range of diagnostic and consumer products. The company's operations are divided into two primary segments: Diagnostic Services and Consumer Products.

The Diagnostic Services segment offers COVID-19 diagnostic testing to a broad range of customers across the United States, including health plans, third-party payers, and government organizations. This segment is focused on delivering timely and accurate diagnostic information, critical during the ongoing pandemic and beyond.

The Consumer Products segment is engaged in the research, development, manufacture, distribution, marketing, and sale of over-the-counter (OTC) healthcare products and dietary supplements within the United States. In addition to these offerings, ProPhase Labs also provides personal genomics products and services, enabling consumers to gain insights into their genetic makeup.

ProPhase Labs is committed to advancing health and wellness through innovative products and services. Recent achievements include the development of the BE-Smart Esophageal Cancer Test, leveraging the company's AI platform and extensive genomics database. This test represents a significant step forward in cancer diagnostics and showcases the company's commitment to leveraging advanced technologies for improved healthcare outcomes.

Moreover, ProPhase Labs has projects such as Project ZenQ-AI and Equivir, which underline the company's focus on continuous research and innovation. These initiatives highlight ProPhase Labs' role in pushing the boundaries of medical science and consumer health products.

Financially, ProPhase Labs maintains a solid position, with ongoing projects and partnerships further strengthening its market presence. The company actively communicates with its retail investors through multiple channels, ensuring transparency and engagement with its stakeholders.

For more information, visit ProPhase Labs.

News

ProPhase Labs Announces Financial Results for the Year Ended December 31, 2023 and Significant Progress in Its Strategic Initiatives

Rhea-AI Summary
ProPhase Labs, Inc. (PRPH) reports financial and operational results for 2023, highlighting significant capacity expansion and growth at Pharmaloz Manufacturing. Nebula Genomics secures major international B2B deal, while Pharmaloz accelerates capacity expansion. The Company transitions to a genomics lab, anticipates rapid revenue growth, and plans a conference call on March 15, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.7%
Tags
earnings
-
News

PROPHASE LABS TO PRESENT 2023 YEAR END FINANCIAL RESULTS ON MARCH 15, 2024

Rhea-AI Summary
ProPhase Labs Inc. (NASDAQ: PRPH) will present its full year 2023 financial results on a virtual conference call on March 15, 2024, hosted by Renmark Financial. Stakeholders, investors, and followers are invited to register and attend the live event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.64%
Tags
conferences earnings
-
News

ProPhase Labs Announces Significant Progress in BE-Smart Esophageal Cancer Test Development USPTO grants additional broad patents for BE-SMART

Rhea-AI Summary
ProPhase Labs, Inc. (NASDAQ: PRPH) announces advancements in commercializing BE-Smart esophageal cancer diagnostic test. The test shows promising results in detecting early signs of cancer in individuals with Barrett's esophagus, potentially revolutionizing cancer diagnosis and management.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.6%
Tags
none
News

ProPhase Labs Announces Preliminary Positive Results for Dietary Supplement Equivir

Rhea-AI Summary
ProPhase Labs, Inc. (NASDAQ: PRPH) announces positive preliminary results for Equivir dietary supplement trial, showing potential to reduce upper respiratory illnesses. Second trial completion expected in Q2 2024, with plans for commercialization and product launch in late 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.24%
Tags
none
-
News

Sidus Space Appoints Bill White as Chief Financial Officer

Rhea-AI Summary
Sidus Space (NASDAQ: SIDU) has announced the appointment of Bill White as Chief Financial Officer, effective February 20, 2024. Mr. White brings over 30 years of experience in financial management, operations, and business development. He has previously served as CFO of ProPhase Labs, Inc. and Intellicheck, Inc. Teresa Burchfield will step down as CFO after two years with the Company but will remain in an advisory role to assist with the transition. The CEO expressed gratitude for Burchfield's contributions and looks forward to the future growth and value creation under White's leadership.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.96%
Tags
management
-
News

ProPhase Labs Ushers in New Genomics Era with Jason Karkus at the Helm of Nebula Genomics

Rhea-AI Summary
ProPhase Labs, Inc. (NASDAQ: PRPH) announces that Jason Karkus, known for his success in the Covid testing space, becomes President of Nebula Genomics, a subsidiary of ProPhase. Karkus will focus on expanding the business-to-business operations and direct-to-consumer Whole Genome Sequencing (WGS) model. ProPhase's WGS lab, equipped with cutting-edge sequencing platforms, aims to revolutionize the genomics industry. The company's strategic move from Covid testing to advanced WGS is expected to drive growth and shareholder returns.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.42%
Tags
none
News

Pharmaloz Manufacturing Accelerates Expansion, Improves Pricing, Boosts Profitability and Secures New Contracts

Rhea-AI Summary
ProPhase Labs, Inc. (NASDAQ: PRPH) announces significant progress at Pharmaloz Manufacturing, Inc. (PMI), its wholly owned subsidiary. PMI has won two new contracts in January, projecting a significant increase in revenues and profitability. The company is in late-stage discussions with two additional large global brands, aiming to triple run-rate of revenues before year-end 2024. PMI has implemented price increases across its product line, acquired automation equipment, and signed deals with top-tier lozenge brands, projecting to inject an additional $5 million in annual revenue and more than $1.25 million in additional yearly pre-tax net profits. The company also plans to double capacity by Q2 2024 and further increase annual production capabilities to a range of $60-$80 million by Q4 2024. The CEO envisions scaling the business to a potential $80-$100 million production capacity with healthy net profit margins by the next 18-24 months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.13%
Tags
none
-
News

ProPhase poised to ramp up growth at Pharmaloz and Nebula Genomics in 2024

Rhea-AI Summary
ProPhase Labs, Inc. (NASDAQ: PRPH) announces the hiring of Jed Latkin as COO to help develop and grow its subsidiaries, including the commercialization of the BE-SMART esophageal cancer test in 2024. Mr. Latkin, a long-time industry veteran with a Columbia MBA, has been awarded a stock option to purchase up to 500,000 shares of the Company's common stock as an inducement to his employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.77%
Tags
none
-
News

ProPhase Labs Announces Financial Results for the Three Months Ended September 30, 2023

Rhea-AI Summary
ProPhase Labs, Inc. (NASDAQ: PRPH) reported a successful transition to development stage, growth-oriented subsidiaries, with significant upside growth potential. The company aims for liquidity events in one or more subsidiaries in 2024 at implied valuations that may exceed the entire current market cap. Pharmaloz Manufacturing is on track to increase capacity from $10 million to over $75 million in 2024, with indications of demand for entire planned expansion. Nebula Genomics opens a new Whole Genome Sequencing lab in NY and sees significant demand. The company anticipates generating significant net profits by the second half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.82%
Tags
earnings
News

ProPhase Labs to Host Third Quarter 2023 Financial Results Conference Call on Thursday, November 9, 2023 at 11:00 a.m. Eastern Time

Rhea-AI Summary
ProPhase Labs, Inc. will hold a conference call on November 9, 2023, to discuss its third-quarter results and provide a business update. The call will be hosted by CEO Ted Karkus. Participants can register for the call online or dial in. The call will be broadcast live and available for replay on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.57%
Tags
conferences earnings

FAQ

What is the current stock price of ProPhase Labs (PRPH)?

The current stock price of ProPhase Labs (PRPH) is $0.6105 as of December 20, 2024.

What is the market cap of ProPhase Labs (PRPH)?

The market cap of ProPhase Labs (PRPH) is approximately 15.3M.

What does ProPhase Labs, Inc. do?

ProPhase Labs is a diversified health and medical science company offering diagnostic testing, genomics testing, and consumer healthcare products.

What are the main segments of ProPhase Labs' operations?

ProPhase Labs operates two main segments: Diagnostic Services and Consumer Products.

What services does the Diagnostic Services segment provide?

The Diagnostic Services segment offers COVID-19 diagnostic testing to various customers, including health plans, third-party payers, and government organizations.

What products are offered in the Consumer Products segment?

The Consumer Products segment provides OTC healthcare products, dietary supplements, and personal genomics products and services.

What is the BE-Smart Esophageal Cancer Test?

The BE-Smart Esophageal Cancer Test is an innovative diagnostic test developed by ProPhase Labs, harnessing AI and extensive genomics data.

What recent projects has ProPhase Labs undertaken?

Recent projects include Project ZenQ-AI and Equivir, highlighting ProPhase Labs' commitment to research and innovation.

How does ProPhase Labs engage with its investors?

ProPhase Labs maintains clear communication with retail investors through various channels, promoting transparency and engagement.

How does ProPhase Labs contribute to healthcare?

ProPhase Labs contributes by offering diagnostic testing services and developing innovative healthcare products and genomic insights.

Stock PRPH logo
ProPhase Labs, Inc.

Nasdaq:PRPH

PRPH Rankings

#5422 Ranked by Market Cap
N/A Ranked by Dividends

PRPH Stock Data

15.28M
20.54M
14.34%
7.64%
0.81%
Diagnostics & Research
Pharmaceutical Preparations
Link
United States of America
NEW YORK